跳至主要内容
临床试验/NCT04784000
NCT04784000已完成1 期

A Phase 1 Study Assessing the Effect of Carbamazepine, a P-Glycoprotein Inducer, on the Pharmacokinetics of AT-527 in Healthy Adult Subjects

Atea Pharmaceuticals, Inc.1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2021年3月1日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
20
试验地点
1
主要终点
Pharmacokinetics (PK) of AT-527 (RO7496998)

研究概览

简要总结

This study will determine the effect of carbamazepine on the PK of AT-527 (RO7496998) in healthy adult subjects.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug
  • Females must have a negative pregnancy test at Screening and prior to dosing
  • Minimum body weight of 50 kg and body mass index (BMI) of 18-29 kg/m2
  • Willing to comply with the study requirements and to provide written informed consent

排除标准

  • Pregnant or breastfeeding
  • Infected with hepatitis B virus, hepatitis C virus, HIV or COVID-19
  • Abuse of alcohol or drugs
  • Use of other investigational drugs within 28 days of dosing
  • Use of other prescription drugs with 28 days of dosing
  • Other clinically significant medical conditions or laboratory abnormalities

结局指标

主要结局

Pharmacokinetics (PK) of AT-527 (RO7496998)

时间窗: Day 1 vs Day 26

Maximum plasma concentration (Cmax)

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验